When to stress over triptans: A markov analysis of cardiovascular risk in migraine treatment

Headache

Volumn 44, Issue 7, 2004, Pages 652-660

  Orlando, Lori A ^a   Matchar, David B ^a  

^a First Union Tower ^*

Author keywords

5HT1 receptor agonist; Coronary artery disease; Migraine; Myocardial infarction; Triptan

Indexed keywords

SEROTONIN 1 AGONIST; TRIPTAN DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG EFFICACY; HEART DEATH; HEART DISEASE; HEART FUNCTION TEST; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MIGRAINE; MONTE CARLO METHOD; MORTALITY; PRIORITY JOURNAL; PROBABILITY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TREATMENT INDICATION;

CARDIOVASCULAR DISEASES; HUMANS; MARKOV CHAINS; MIGRAINE DISORDERS; MODELS, THEORETICAL; RISK FACTORS; SEROTONIN AGONISTS;

EID: 3142764585     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2004.04123.x     Document Type: Article

References (47)

1. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA. 1992;267:64-69.
2. Hu XH, Markson LE, Lipton RB, Cetentano DD, Reed ML. Burden of migraine in the United States: disability and economic costs. Arch Inter Med. 1999;159:813-818.
3. Swan L, Hood S, Birnie DH, et al. The haemodynamic effect of the 5HT1 agonist BMS-180048: a class effect of triptans? Br J Clin Pharmacol. 1999;47:189-194.
4. Longmore J, Maguire JJ, MacLeod A, et al. Comparison of the vasoconstrictor effects of the selective 5-HT1D-receptor agonist L-775,606 with the mixed 5-HT1B/1D-receptor agonist sumatriptan and 5-HT in human isolated coronary artery. Br J Clin Pharmacol. 2000;49:126-131.
5. Maassen VanDenBrink A, Bax WA, Ramrattan NN, Ferrari MD, Saxena PR. Human isolated coronary artery contraction to sumatriptan: a post hoc analysis. Cephalalgia. 1999;19:651-654.
6. The Triptan Cardiovascular Safety Expert Panel. Consensus statement: cardiovascular safety profile of 5-HT1B/1D agonists in the acute treatment of migraine. Headache. 2004;44:414-425
7. FDA, Adverse Event Reporting System.
8. Visser WH, Jaspers NM, de Vriend RH, Ferrari MD. Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients. Cephalalgia. 1996;16:554-559.
9. Dahlof CG, Falk L, Risenfors M, Lewis CP. Safety trial with the 5HT1B/1D agonist avitriptan (BMS-180048) in patients with migraine who have experienced pressure, tightness, and/or pain in the chest, neck, and/or throat following sumatriptan. [comment]. Cephalalgia. 1998;18:546-551.
10. Matchar DB, Young WB, Rosenburg JH, et al. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management of acute attacks. 2000.
11. Young WB, Mannix L, Adelman JU, Shechter AL. Cardiac risk factors and the use of triptans: a survey study. Headache. 2000;40:587-591.
12. Cook NR, Bensenor IM, Lotufo PA, et al. Migraine and coronary heart disease in women and men. Headache. 2002;42:715-727.
13. Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology. 2001;56(Suppl 1):S20-S28.
14. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-1847.
15. CDC, Center for Health Statistics Life Tables. 2000.
16. A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. The Multinational Oral Sumatriptan and Cafergot Comparative Study Group. Eur Neurol. 1991;31:314-322.
17. Goadsby PJ, Ferrari MD, Olesen J, et al. Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee. [comment]. Neurology. 2000;54:156-163.
18. Tfelt-Hansen P. Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat. Cephalalgia. 1998;18:532-538.
19. Schulman EA, Cady RK, Henry D, et al. Effectiveness of sumatriptan in reducing productivity loss due to migraine: results of a randomized, double-blind, placebo-controlled clinical trial. [comment]. Mayo Clin Proc. 2000;75:782-789.
20. Pascual J, Falk RM, Piessens F, et al. Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomized, double-blind, placebo-controlled study. Cephalalgia. 2000;20:588-596.
21. Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002;22:633-658.
22. Goadsby PJ, Zagami AS, Donnan GA, et al. Oral sumatriptan in acute migraine. Lancet. 1991;338:782-783.
23. Greiner DL, Addy SN. Sumatriptan use in a large group-model health maintenance organization. Am J Health-Sys Pharm. 1996;53:633-638.
24. Tansey MJ, Pilgrim AJ, Lloyd K. Sumatriptan in the acute treatment of migraine. J Neurol Sci. 1993;114:109-116.
25. Visser WH, de Vriend RH, Jaspers MW, Ferrari MD. Sumatriptan in clinical practice: a 2-year review of 453 migraine patients. Neurology. 1996;47:46-51.
26. Clouse JC, Osterhaus JT. Healthcare resource use and costs associated with migraine in a managed healthcare setting. Ann Pharmacother. 1994;28:659-664.
27. Lofland JH, Kim SS, Batenhorst AS, et al. Cost-effectiveness and cost-benefit of sumatriptan in patients with migraine. Mayo Clin Proc. 2001;76:1093-1101.
28. Caro JJ, Getsios D, Raggio G, Caro G, Black L. Treatment of migraine in Canada with naratriptan: a cost-effectiveness analysis. Headache. 2001;41:456-464.
29. Evans KW, Boan JA, Erans JL, Shuaib A. Economic evaluation of oral sumatriptan compared with oral caffeine/ergotamine for migraine. Pharmacoeconomics. 1997;12:565-577.
30. Legg RF, Sclar DA, Nemec NL, Tarnai J, Mackowiak JI. Cost-effectiveness of sumatriptan in a managed care population. Am J Manag Care. 1997;3:117-122.
31. Assey ME, Walters GL, Hendrix GH, et al. Incidence of acute myocardial infarction in patients with exercise-induced silent myocardial ischemia. Am J Card. 1987;59:497-500.
32. Fleg JL. Prevalence and prognostic significance of exercise-induced silent myocardial ischemia in apparently healthy subjects. Am J Cardiol. 1992;69:14B-18B.
33. Heller LI, Tresgallo M, Sciacca RR, et al. Prognostic significance of silent myocardial ischemia on a thallium stress test. Am J Cardiol. 1990;65:718-721.
34. Katzel LI, Sorkin JD, Goldberg AP. Exercise-induced silent myocardial ischemia and future cardiac events in healthy, sedentary, middle-aged and older men [comment]. J Am Geriatr Soc. 1999;47:923-929.
35. Franzosi MG, Santoro E, Devita C, et al. Ten-year follow-up of the first megatrial testing thrombolytic therapy in patients with acute myocardial infarction: results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto-1 study. The GISSI Investigators [comment]. Circulation. 1998;98:2659-2665.
36. Antman EM, McCabe CH, Braunwald E. Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: observations from the TIMI 8 trial. The thrombolysis in myocardial infarction [comment]. Am Heart J. 2002;143:229-234.
37. Stewart WF, Lipton RB, Liberman J. Variation in migraine prevalence by race. Neurology. 1996;47:52-59.
38. Tomkins GE, Jackson JL, O'Malley PG, Baldon E, Santoro JE. Treatment of chronic headache with antidepressants: a meta-analysis [comment]. Am J Med. 2001;111:54-63.
39. Weiss AT, Leitersdorf I, Gotsman MS, et al. Prevention of congestive heart failure by early, prehospital thrombolysis in acute myocardial infarction: a long-term follow-up study. Int J Cardiol. 1998;65(suppl 1):S43-S48.
40. Guidry UC, Evans JC, Larson MG, et al. Temporal trends in event rates after Q-wave myocardial infarction: the Framingham Heart Study. Circulation. 1999;100:2054-2059.
41. The Diclofenac-K/Sumatriptan Migraine Study Group. Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. Cephalalgia. 1999;19:232-240.
42. Diener HC and The ASASUMAMIG Study Group. Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study. Cephalalgia. 1999;19:581-588; discussion 542.
43. Fleischmann KE, Hunink MG, Kuntz KM, Douglas PS. Exercise echocardiography or exercise SPECT imaging? A meta-analysis of diagnostic test performance [comment]. JAMA. 1998;280:913-920.
44. Schwartz RS, Jackson WG, Celio PV, Richardson LA, Hickman JR Jr. Accuracy of exercise 201T1 myocardial scintigraphy in asymptomatic young men. Circulation. 1993;87:165-172.
45. Mittmann N, Trakas K, Risebrough N, Liu BA. Utility scores for chronic conditions in a community-dwelling population. Pharmacoeconomics. 1999;15:369-376.
46. Shephard RJ, Kavanagh T, Mertens DJ. On the prediction of physiological and psychological responses to aerobic training in patients with stable congestive heart failure. J Cardiopulm Rehab. 1998;18:45-51.
47. Sieber WJ, David KM, Adams JE, Kaplan RM, Ganiats TG. Assessing the impact of migraine on health-related quality of life: An additional use of the quality of well-being scale-self-administered. Headache. 2000;40:662-671.